Omega-3 Fatty Acids Reduce the Number of Crisis and Steady State Hemolysis In Sickle Cell Disease

• Published in: Blood 2010-11, Vol.116 (21), p.1624-1624
• Main Authors: Okpala, Iheanyi, Ibegbulam, Obike, Duru, Augustine, Ocheni, Sunday, Emodi, Ifeoma, Ikefuna, Anthony, Kangiwa, Umar, Asinobi, Isaac, Madu, Anazoeze, Okoye, Augustine, Nwagha, Tessy, Oguonu, Uche, Uamai, Ify, Agwu, Obineche, Nonyelum, Charles, Anike, Uche, Agu, Kingsley, Anigbo, Chukwudi, Chukwura, Awele, Ugwu, Ogechukwu, Herrada, S.
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V116.21.1624.1624

Abstract 1624 Previous studies showed that: (1) increased blood levels of the omega-3 (n3) fatty acids (FA) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are associated with increased steady-state Hb levels and reduced prevalence of the complications of sickle cell disease (SCD); (2) EPA and DHA reduced the number of crisis in a pilot group of 5 HbSS patients. The primary aim of this study was to assess the effects of EPA and DHA in a larger number of patients. SCD causes recurrent vaso-occlusion, ischemia-reperfusion injury and inflammation (Osarogiagbon et al. Blood. 2000, 96: 314–320). A metabolite of DHA (10,17S-docosatriene) protects against ischemia-reperfusion injury by inhibiting leukocyte infiltration and expression of pro-inflammatory genes (Marcheselli et al, J Bio Chem. 2003; 278: 43807–43817. Our hypothesis was that anti-inflammatory properties contribute to the mechanism(s) of action of DHA/EPA in SCD. The secondary objective was to test this hypothesis. Following Institutional Review Board approval and informed consent, 20 HbSS patients (10 Males, 10 Females) were enlisted to receive oral EPA 15mg /kg/day and DHA 10 mg/kg/day with standard treatment of SCD, and reviewed at 2-monthly intervals for 6 months. Standard treatment included folic acid 5 mg daily, pyrimethamine-sulfadoxine (25mg/500mg) 2–3 tablets monthly for malaria prophylaxis, and appropriate management of acute clinical events. To assess the placebo effect of regular clinical monitoring, another group of 8 HbSS patients (2 Males, 6 Females) were enlisted to be reviewed 2-monthly for 6 months, but observed on standard treatment only. Inclusion criteria for both groups were 3 or more crisis/yr and age>5yrs. Exclusion criteria: pregnancy, hydroxyurea or regular transfusion therapy, any other disease e.g diabetes. To reduce the confounding effect of individual variability in severity of SCD, the study was so designed that each participant was his/her own control. Using the Mann-Whitney test, we compared pre- and post-treatment numbers of crisis over 6 months, steady state levels of Hb and plasma unconjugated bilirubin. To test the hypothesis that anti-inflammatory effects contribute to the mode of action DHA/EPA, we compared 3 indices of inflammation pre-and post-treatment: plasma level of interleukin-6 measured by ELISA, peripheral blood neutrophil and platelet counts determined with an automated cell counter. In the omega-3 FA group 4 participants dropped out or were